JP2020520957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520957A5 JP2020520957A5 JP2019564529A JP2019564529A JP2020520957A5 JP 2020520957 A5 JP2020520957 A5 JP 2020520957A5 JP 2019564529 A JP2019564529 A JP 2019564529A JP 2019564529 A JP2019564529 A JP 2019564529A JP 2020520957 A5 JP2020520957 A5 JP 2020520957A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000004043 oxo group Chemical group O=* 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 108010024121 Janus Kinases Proteins 0.000 claims 2
- 102000015617 Janus Kinases Human genes 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- -1 -CF 3 Chemical class 0.000 claims 1
- 241001481833 Coryphaena hippurus Species 0.000 claims 1
- 206010011703 Cyanosis Diseases 0.000 claims 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017085277 | 2017-05-22 | ||
| CNPCT/CN2017/085277 | 2017-05-22 | ||
| US201862644784P | 2018-03-19 | 2018-03-19 | |
| US62/644,784 | 2018-03-19 | ||
| PCT/EP2018/063263 WO2018215390A1 (en) | 2017-05-22 | 2018-05-21 | Therapeutic compounds and compositions, and methods of use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020520957A JP2020520957A (ja) | 2020-07-16 |
| JP2020520957A5 true JP2020520957A5 (enExample) | 2021-07-26 |
| JP7228318B2 JP7228318B2 (ja) | 2023-02-24 |
| JP7228318B6 JP7228318B6 (ja) | 2023-03-10 |
Family
ID=62486555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564529A Active JP7228318B6 (ja) | 2017-05-22 | 2018-05-21 | 処置用化合物及び組成物、並びにその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20180334465A1 (enExample) |
| EP (1) | EP3630767A1 (enExample) |
| JP (1) | JP7228318B6 (enExample) |
| CN (1) | CN110678467B (enExample) |
| TW (1) | TW201900648A (enExample) |
| WO (1) | WO2018215390A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| RU2769696C2 (ru) | 2017-05-22 | 2022-04-05 | Ф. Хоффманн-Ля Рош Аг | Терапевтические соединения и композиции и способы их применения |
| WO2020163778A1 (en) * | 2019-02-07 | 2020-08-13 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| PE20220577A1 (es) | 2019-06-18 | 2022-04-20 | Hoffmann La Roche | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos |
| TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022008283A1 (en) | 2020-07-07 | 2022-01-13 | Universitat Rovira I Virgili | Reagents for the polyfluoroalkylthiolation of organic compounds and method for production thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| AU6311996A (en) | 1995-07-06 | 1997-02-05 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| JP4486817B2 (ja) | 2001-12-20 | 2010-06-23 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体 |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| RU2560153C2 (ru) | 2008-06-20 | 2015-08-20 | Дженентек, Инк. | Триазолпиридиновые соединения, ингибирующие jak, и способы |
| RU2539568C2 (ru) | 2008-10-31 | 2015-01-20 | Дженентек, Инк. | Пиразолопиримидиновые соединения-ингибиторы jak и способы |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| RS59690B1 (sr) | 2012-11-09 | 2020-01-31 | Medicines For Malaria Venture Mmv | Derivativi heteroarila i njihova upotreba |
| PE20211782A1 (es) | 2014-05-23 | 2021-09-08 | Hoffmann La Roche | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos |
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| EP3416967B1 (en) * | 2016-02-18 | 2022-02-09 | F. Hoffmann-La Roche AG | Therapeutic compounds, compositions and methods of use thereof |
-
2018
- 2018-05-21 EP EP18728330.4A patent/EP3630767A1/en not_active Withdrawn
- 2018-05-21 US US15/984,728 patent/US20180334465A1/en not_active Abandoned
- 2018-05-21 CN CN201880033713.4A patent/CN110678467B/zh not_active Expired - Fee Related
- 2018-05-21 JP JP2019564529A patent/JP7228318B6/ja active Active
- 2018-05-21 WO PCT/EP2018/063263 patent/WO2018215390A1/en not_active Ceased
- 2018-05-21 TW TW107117164A patent/TW201900648A/zh unknown
-
2019
- 2019-10-30 US US16/668,714 patent/US20200062779A1/en not_active Abandoned
-
2021
- 2021-09-29 US US17/449,398 patent/US20220024945A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520957A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2019519598A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2018515495A5 (enExample) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2014504622A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2017533930A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| CN109328187A (zh) | 一种具有fgfr抑制活性的新型化合物及其制备和应用 | |
| JP2015537020A5 (enExample) | ||
| JP2018535963A5 (enExample) | ||
| JP2009541223A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2017523169A5 (enExample) |